Poniard Pharma (PARD) SPEAR Phase III of Picoplatin Did Not Meet Survival Endpoint
Tweet Send to a Friend
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD) today announced that its pivotal Phase 3 SPEAR (Study of Picoplatin Efficacy After Relapse) trial ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
